+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Schizophrenia Drugs Market Report and Forecast 2023-2031

  • PDF Icon


  • 147 Pages
  • April 2023
  • Region: Global
  • Expert Market Research
  • ID: 5786920
Global Schizophrenia Drugs Market Report and Forecast 2023-2031
Global Schizophrenia Drugs Market Outlook
The value of the global schizophrenia drugs market was USD 7.87 billion in 2022, driven by the prevalence of schizophrenia across the globe. The market is expected to grow at a CAGR of 3.92% during the forecast period of 2023-2031 to reach value of USD 11.12 billion by 2031.

Schizophrenia Drugs: Introduction

Schizophrenia is a severe and chronic mental disorder that affects a person's thinking, behaviour, and emotions. It is a highly complex disorder that requires long-term treatment and management. Schizophrenia drugs are a class of medications that are used to manage the symptoms of schizophrenia, such as delusions, hallucinations, and disordered thinking.

The introduction of antipsychotic drugs in the 1950s revolutionized the treatment of schizophrenia, leading to improved outcomes for patients. Since then, several different types of schizophrenia drugs have been developed, including typical antipsychotics, atypical antipsychotics, and combination therapies. These drugs work by modulating the levels of neurotransmitters in the brain, such as dopamine and serotonin, which are believed to play a role in the development of schizophrenia
While schizophrenia drugs are highly effective in managing the symptoms of the disorder, they are not a cure, and many patients require lifelong treatment to maintain symptom control. In addition, these drugs can cause side effects, such as weight gain, metabolic changes, and movement disorders, which can have a significant impact on patients' quality of life. As a result, there is ongoing research into the development of new and improved schizophrenia drugs that can provide better symptom control with fewer side effects.

Schizophrenia Drugs: Application and Uses

Schizophrenia drugs are used to treat the symptoms associated with schizophrenia, which is a chronic mental disorder that affects how a person thinks, feels, and behaves. The application and uses of schizophrenia drugs include:
  • Antipsychotics: These drugs are the mainstay of treatment for schizophrenia and are used to control the positive symptoms of the disorder, such as hallucinations and delusions
  • Mood stabilizers: These drugs are used to treat the mood swings that may occur in people with schizophrenia, such as manic or depressive episodes
  • Antidepressants: These drugs may be used to treat the depressive symptoms that may occur in people with schizophrenia
  • Anxiolytics: These drugs may be used to treat anxiety symptoms that may occur in people with schizophrenia
  • Cognitive enhancers: These drugs may be used to improve cognitive function, such as memory and attention, in people with schizophrenia
Overall, the goal of schizophrenia drugs is to improve the quality of life for people with schizophrenia by reducing symptoms and helping them function better in their daily lives.

Global Schizophrenia Drugs Market Segmentations

Market Breakup by Therapeutic Class

  • Second-generation Antipsychotics
  • Third-generation Antipsychotics
  • Others

Market Breakup by Treatment

  • Oral
  • Injectables

Market Breakup by Distribution Channels

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online
  • Others

Market Breakup by Region

North America

  • United States of America
  • Canada


  • United Kingdom
  • Germany
  • France
  • Italy
  • Others

Asia Pacific

  • China
  • Japan
  • India
  • Australia
  • Others

Latin America

  • Brazil
  • Argentina
  • Mexico
  • Others

Middle East and Africa

  • Saudi Arabia
  • United Arab Emirates
  • Nigeria
  • South Africa
  • Others

Global Schizophrenia Drugs: Market Scenario

The growing prevalence of schizophrenia, rising healthcare expenditure, increasing awareness about mental health disorders, and advancements in drug delivery techniques are some of the factors driving the growth of the market. Additionally, the development of novel drug candidates and personalized medicine for the treatment of schizophrenia is expected to create new growth opportunities in the market.

North America holds the largest share of the market, followed by Europe, due to the high prevalence of schizophrenia in these regions and the availability of advanced healthcare infrastructure. The Asia-Pacific region is expected to witness the fastest growth during the forecast period, driven by the growing demand for effective treatment options and increasing healthcare spending in emerging economies such as China and India.

Key Players in the Global Schizophrenia Drugs Market

The report gives an in-depth analysis of the key players involved in the global schizophrenia drugs market. The companies included in the market are as follows:
  • Eli Lilly and Company
  • AbbVie Inc
  • Alkermes PLC
  • Otsuka Pharmaceutical Co., Ltd
  • Johnson & Johnson Services, Inc
  • Pfizer Inc
  • AstraZeneca
  • Bristol Myers Squibb
  • Sumitomo Dainippon Pharma Co., Ltd
  • Vanda Pharmaceuticals Inc

This product will be delivered within 5-7 business days.

Table of Contents

1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Schizophrenia Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Schizophrenia Epidemiology Analysis
5.1 Epidemiology Overview (2016-2031)
5.2 North America Schizophrenia Epidemiology (2016-2031)
5.3 Europe Schizophrenia Epidemiology (2016-2031)
5.4 Asia-Pacific Schizophrenia Epidemiology (2016-2031)
5.5 Latin America Schizophrenia Epidemiology (2016-2031)
5.6 Middle East & Africa Schizophrenia Epidemiology (2016-2031)
6 Global Schizophrenia Drugs Market Overview
6.1 Global Schizophrenia Drugs Market Historical Value (2016-2022)
6.2 Global Schizophrenia Drugs Market Forecast Value (2023-2031)
7 Global Schizophrenia Drugs Market Landscape
7.1 Schizophrenia Drugs: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Schizophrenia Drugs: Product Landscape
7.2.1 Analysis by Therapeutic Class
7.2.2 Analysis by Treatment
7.2.3 Analysis by Distribution Channels
8 Schizophrenia Drugs Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Global Schizophrenia Drugs Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Global Schizophrenia Drugs Market Segmentation
11.1 Global Schizophrenia Drugs Market by Therapeutic Class
11.1.1 Market Overview
11.1.2 Second-generation Antipsychotics
11.1.3 Third-generation Antipsychotics
11.1.4 Others
11.2 Global Schizophrenia Drugs Market by Treatment
11.2.1 Market Overview
11.2.2 Oral
11.2.3 Injectables
11.3 Global Schizophrenia Drugs Market by Distribution Channels
11.3.1 Market Overview
11.3.2 Hospital Pharmacies
11.3.3 Retail Pharmacies
11.3.4 Online
11.3.5 Others
11.4 Global Schizophrenia Drugs Market by Region
11.4.1 Market Overview
11.4.2 North America
11.4.3 Europe
11.4.4 Asia Pacific
11.4.5 Latin America
11.4.6 Middle East and Africa
12 North America Schizophrenia Drugs Market
12.1 Market Share by Country
12.2 United States of America
12.3 Canada
13 Europe Schizophrenia Drugs Market
13.1 Market Share by Country
13.2 United Kingdom
13.3 Germany
13.4 France
13.5 Italy
13.6 Others
14 Asia Pacific Schizophrenia Drugs Market
14.1 Market Share by Country
14.2 China
14.3 Japan
14.4 India
14.5 ASEAN
14.6 Australia
14.7 Others
15 Latin America Schizophrenia Drugs Market
15.1 Market Share by Country
15.2 Brazil
15.3 Argentina
15.4 Mexico
15.5 Others
16 Middle East and Africa Schizophrenia Drugs Market
16.1 Market Share by Country
16.2 Saudi Arabia
16.3 United Arab Emirates
16.4 Nigeria
16.5 South Africa
16.6 Others
17 Regulatory Framework
17.1 Regulatory Overview
17.1.1 US FDA
17.1.2 EU EMA
17.1.5 Others
18 Patent Analysis
18.1 Analysis by Type of Patent
18.2 Analysis by Publication year
18.3 Analysis by Issuing Authority
18.4 Analysis by Patent Age
18.5 Analysis by CPC Analysis
18.6 Analysis by Patent Valuation
18.7 Analysis by Key Players
19 Grants Analysis
19.1 Analysis by year
19.2 Analysis by Amount Awarded
19.3 Analysis by Issuing Authority
19.4 Analysis by Grant Application
19.5 Analysis by Funding Institute
19.6 Analysis by NIH Departments
19.7 Analysis by Recipient Organization
20 Clinical Trials Analysis
20.1 Analysis by Trial Registration Year
20.2 Analysis by Trial Status
20.3 Analysis by Trial Phase
20.4 Analysis by Therapeutic Area
20.5 Analysis by Geography
21 Funding and Investment Analysis
21.1 Analysis by Funding Instances
21.2 Analysis by Type of Funding
21.3 Analysis by Funding Amount
21.4 Analysis by Leading Players
21.5 Analysis by Leading Investors
21.6 Analysis by Geography
22 Partnership and Collaborations Analysis
22.1 Analysis by Partnership Instances
22.2 Analysis by Type of Partnership
22.3 Analysis by Leading Players
22.4 Analysis by Geography
23 Supplier Landscape
23.1 Eli Lilly and Company
23.1.1 Financial Analysis
23.1.2 Product Portfolio
23.1.3 Demographic Reach and Achievements
23.1.4 Mergers and Acquisitions
23.1.5 Certifications
23.2 AbbVie Inc.
23.2.1 Financial Analysis
23.2.2 Product Portfolio
23.2.3 Demographic Reach and Achievements
23.2.4 Mergers and Acquisitions
23.2.5 Certifications
23.3 Alkermes PLC
23.3.1 Financial Analysis
23.3.2 Product Portfolio
23.3.3 Demographic Reach and Achievements
23.3.4 Mergers and Acquisitions
23.3.5 Certifications
23.4 Otsuka Pharmaceutical Co., Ltd.
23.4.1 Financial Analysis
23.4.2 Product Portfolio
23.4.3 Demographic Reach and Achievements
23.4.4 Mergers and Acquisitions
23.4.5 Certifications
23.5 Johnson & Johnson Services, Inc.
23.5.1 Financial Analysis
23.5.2 Product Portfolio
23.5.3 Demographic Reach and Achievements
23.5.4 Mergers and Acquisitions
23.5.5 Certifications
23.6 Pfizer Inc.
23.6.1 Financial Analysis
23.6.2 Product Portfolio
23.6.3 Demographic Reach and Achievements
23.6.4 Mergers and Acquisitions
23.6.5 Certifications
23.7 AstraZeneca
23.7.1 Financial Analysis
23.7.2 Product Portfolio
23.7.3 Demographic Reach and Achievements
23.7.4 Mergers and Acquisitions
23.7.5 Certifications
23.8 Bristol Myers Squibb
23.8.1 Financial Analysis
23.8.2 Product Portfolio
23.8.3 Demographic Reach and Achievements
23.8.4 Mergers and Acquisitions
23.8.5 Certifications
23.9 Sumitomo Dainippon Pharma Co., Ltd.
23.9.1 Financial Analysis
23.9.2 Product Portfolio
23.9.3 Demographic Reach and Achievements
23.9.4 Mergers and Acquisitions
23.9.5 Certifications
23.10 Vanda Pharmaceuticals Inc.
23.10.1 Financial Analysis
23.10.2 Product Portfolio
23.10.3 Demographic Reach and Achievements
23.10.4 Mergers and Acquisitions
23.10.5 Certifications
24 Schizophrenia Drugs - Distribution Model (Additional Insight)
24.1 Overview
24.2 Potential Distributors
24.3 Key Parameters for Distribution Partner Assessment
25 Key Opinion Leaders (KOL) Insights (Additional Insight)
26 Company Competitiveness Analysis (Additional Insight)
26.1 Very Small Companies
26.2 Small Companies
26.3 Mid-Sized Companies
26.4 Large Companies
26.5 Very Large Companies
27 Payment Methods (Additional Insight)
27.1 Government Funded
27.2 Private Insurance
27.3 Out-of-Pocket

Companies Mentioned

  • Eli Lilly and Company
  • Abbvie Inc.
  • Alkermes plc
  • Otsuka Pharmaceutical Co. Ltd.
  • Johnson & Johnson Services, Inc.
  • Pfizer Inc.
  • Astrazeneca
  • Bristol Myers Squibb
  • Sumitomo Dainippon Pharma Co. Ltd.
  • Vanda Pharmaceuticals Inc.



Table Information